when you compare the opportunity of this at IPO with the cancet drill results in hand, there has been nothing since, that has presented a bird in the hand, so obviously undervalued.
We see many stocks who were priced where we were enter the lithium space, but not with that bird in the hand.
Thats why, they had me at cancet from the beginning. And it will take careful patience, to review to present another in this class at that price opportunity. It spelled out, path of least resistance to development.
Some others will rise on the nearology factor, and those are bets on their own. But they are not certainty. Cancet was.
Having positioned, it is simple a lock, to ride this train to whatever station towards our mountain summit valuation, in stages as we both replicate the path of CXO, and rise our resource tonnage valuation, to determine if there is a better bet out there. Hard to find at this time. A steady growth that train that moves steadily forward, vs an alternate which must show better return, on RISK + Growth. And use of your capital.
- Forums
- ASX - By Stock
- WR1
- Ann: Strong lithium mineralisation from first Adina assays
Ann: Strong lithium mineralisation from first Adina assays, page-792
-
- There are more pages in this discussion • 118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WR1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
70.0¢ |
Change
-0.030(4.11%) |
Mkt cap ! $151.4M |
Open | High | Low | Value | Volume |
73.0¢ | 73.0¢ | 69.0¢ | $331.1K | 468.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 50102 | 69.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
70.0¢ | 3620 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6790 | 0.695 |
6 | 44002 | 0.690 |
2 | 24050 | 0.685 |
4 | 18720 | 0.680 |
2 | 24393 | 0.675 |
Price($) | Vol. | No. |
---|---|---|
0.700 | 3848 | 4 |
0.705 | 2555 | 2 |
0.710 | 21600 | 2 |
0.725 | 3361 | 2 |
0.730 | 20000 | 1 |
Last trade - 15.15pm 15/07/2024 (20 minute delay) ? |
Featured News
WR1 (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online